EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis Huimin YangJinxiu ZhuFei He Original Article 20 September 2021 Pages: 1001 - 1016
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma Jutatip PanaamponRyusho KariyaSeiji Okada Original Article 20 September 2021 Pages: 1017 - 1031
Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer Kawaljit KaurMeng-Wei KoAnahid Jewett Original Article 24 September 2021 Pages: 1033 - 1047
Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma Michael W. KnitzLaurel B. DarraghSana D. Karam Original Article 24 September 2021 Pages: 1049 - 1061
Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice Kang ChenWei WeiJian-Hong Zhong Original Article 24 September 2021 Pages: 1063 - 1074
LncRNA MIR155HG induces M2 macrophage polarization and drug resistance of colorectal cancer cells by regulating ANXA2 Lin ZhouJian LiMei Yang Original Article 25 September 2021 Pages: 1075 - 1091
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience Seoyoung LeeHyo Sup ShimMin Hee Hong Original Article 27 September 2021 Pages: 1093 - 1101
Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma Markus Bo SchoenbergTong ZhuAlexandr V. Bazhin Original Article Open access 28 September 2021 Pages: 1103 - 1113
Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide Jen-Chih TsengJing-Xing YangTsung-Hsien Chuang Original Article Open access 28 September 2021 Pages: 1115 - 1128
The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study Mitsuro FukuharaSatoshi MutoHiroyuki Suzuki Original Article 01 October 2021 Pages: 1129 - 1137
Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia Hana TrikiKen DeclerckBoutheina Cherif Original Article 04 October 2021 Pages: 1139 - 1155
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival Tyler C. HaddadSongzhu ZhaoDwight H. Owen Original Article Open access 07 October 2021 Pages: 1157 - 1165
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma Li ChengTodd CreasyKatie Streicher Original Article Open access 08 October 2021 Pages: 1167 - 1181
Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma Bolun ZhouShugeng Gao Original Article 11 October 2021 Pages: 1183 - 1197
Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment Xueying WangKui CaoSusheng Miao Original Article 13 October 2021 Pages: 1199 - 1220
The Crohn’s-like lymphoid reaction density: a new artificial intelligence quantified prognostic immune index in colon cancer Minning ZhaoSu YaoZaiyi Liu Original Article 13 October 2021 Pages: 1221 - 1231
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor Ding NieQiuyue FangPeng Zhao Original Article Open access 13 October 2021 Pages: 1233 - 1245
Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus Zuan LinXuanye ZhangLi Zhang Original Article 14 October 2021 Pages: 1247 - 1255
Correction to: Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus Zuan LinXuanye ZhangLi Zhang Correction 06 December 2021 Pages: 1257 - 1257
MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues Tony YaoPatrick T. RudakS. M. Mansour Haeryfar Original Article 02 December 2021 Pages: 1259 - 1273
A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer Jianjiao NiYue ZhouZhengfei Zhu Research Report 06 October 2021 Pages: 1275 - 1280
